HSHelius Medical Technologies, Inc. HSDT NASDAQ · Financials · United States
$1.86 +1.64% +$0.03
- Market cap
- $106.6M
- Enterprise value
- $102.9M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 8.8x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -14.2%
- Gross margin
- 95.5%
- Net margin
- -1,302.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.07
- Free float
- 69.1%
About the company
Helius Medical Technologies, Inc. is a biopharmaceutical company focused on the development and commercialization of neurostimulation therapies for the treatment of neurological disorders. Its main product platform is the Portable Neuromodulation Stimulator (PoNS) technology, which utilizes tongue stimulation to influence brain function and the nervous system. This technology has the potential to help patients with various neurological disorders, including traumatic brain injury, multiple sclerosis, and other neurological conditions. The company focuses on conducting clinical trials and obtaining regulatory approvals for its therapeutic products. Its goal is to provide innovative and effective treatment methods to improve the quality of life for patients suffering from neurological disorders. Shares of Helius Medical Technologies, Inc. may be an interesting investment opportunity for investors following the biopharmaceutical industry and neurological medicine.
Sector
Financial Services
Industry
Asset Management
CEO
Dane Carl Andreeff
Employees
21
Headquarters
Newtown
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 97% a year over the last 3 years.
- What to watch: It missed profit estimates 4 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number